hematopoietic stem cell

HSCs originate from mesoderm and are first found in the yolk sac and aorta-gonad-mesonephros (AGM) region during embryogenesis, later migrating to the fetal liver and finally the bone marrow, which becomes the primary site of hematopoiesis after birth. HSCs have two key properties: self-renewal (dividing to produce more HSCs) and differentiation (producing progenitor cells that mature into all formed elements of blood). They differentiate into two main lineages: the common myeloid progenitor (giving rise to erythrocytes, platelets, granulocytes, monocytes) and the common lymphoid progenitor (giving rise to T cells, B cells, NK cells). Differentiation and proliferation are regulated by cytokines and growth factors including erythropoietin (EPO), thrombopoietin (TPO), granulocyte colony-stimulating factor (G-CSF), granulocyte-macrophage colony-stimulating factor (GM-CSF), and various interleukins (IL-3, IL-7). Clinically, HSCs are central to hematopoietic stem cell transplantation (HSCT), used to treat leukemias, lymphomas, aplastic anemia, and certain genetic/immunodeficiency disorders. HSCs can be harvested from bone marrow, peripheral blood (after G-CSF mobilization), or umbilical cord blood. CD34 positivity is used for HSC identification/purification in transplant preparation. Failure of HSC function or bone marrow infiltration (e.g., by malignancy, fibrosis, or aplastic anemia) leads to pancytopenia. Mutations arising in HSCs are implicated in myeloproliferative disorders (e.g., JAK2 mutation in polycythemia vera) and leukemias (e.g., BCR-ABL in CML), reflecting their role as the cell of origin for many hematologic malignancies. Understanding HSC biology is foundational to concepts of bone marrow failure syndromes, myelodysplastic syndromes, and stem cell transplant conditioning regimens (myeloablative vs. non-myeloablative).